Related Experiment Video
Updated: Jul 23, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape
Eman T Al-Antary1,2, Avanti Gupte3,4, Yaddanapudi Ravindranath3,5
1Division of Hematology/Oncology, Children's Hospital of Michigan, Pediatric Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Detroit, MI, USA. Eal-anta@dmc.org.
Abstract:
Acute myeloid leukemia (AML) accounts for 25% of all leukemia diagnosis and is characterized by distinct cytogenetic and molecular profile. Advances in the understanding of the causative driver mutations, risk-based therapy and better supportive care have led to an overall improvement in survival with frontline therapy. Despite these improvements, a significant number fail either because of primary refractory disease to the conventional 7+3 combination of anthracyclines and cytosine arabinoside (Cytarabine; Ara-C) or experience relapse post remission. Salvage therapy is complicated by the cardiotoxicity driven limitations on the reuse of anthracyclines and development of resistance to cytarabine. In this chapter authors will review the recent studies with targeted agents for refractory AML including targets for immunotherapeutic strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Differentiation of Common Myeloid Progenitor Cells
Drug Therapy
Antianxiety Medications

